Medulloblastomas are the most common malignant brain tumours in children 1 . Identifying and understanding the genetic events that drive these tumours is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. Recently, our group and others described distinct molecular subtypes of medulloblastoma on the basis of transcriptional and copy number profiles [2] [3] [4] [5] . Here we use whole-exome hybrid capture and deep sequencing to identify somatic mutations across the coding regions of 92 primary medulloblastoma/normal pairs. Overall, medulloblastomas have low mutation rates consistent with other paediatric tumours, with a median of 0.35 non-silent mutations per megabase. We identified twelve genes mutated at statistically significant frequencies, including previously known mutated genes in medulloblastoma such as CTNNB1, PTCH1, MLL2, SMARCA4 and TP53. Recurrent somatic mutations were newly identified in an RNA helicase gene, DDX3X, often concurrent with CTNNB1 mutations, and in the nuclear co-repressor (N-CoR) complex genes GPS2, BCOR and LDB1. We show that mutant DDX3X potentiates transactivation of a TCF promoter and enhances cell viability in combination with mutant, but not wild-type, b-catenin. Together, our study reveals the alteration of WNT, hedgehog, histone methyltransferase and now N-CoR pathways across medulloblastomas and within specific subtypes of this disease, and nominates the RNA helicase DDX3X as a component of pathogenic b-catenin signalling in medulloblastoma.
Medulloblastomas are aggressive tumours of primitive neuroectodermal origin. More than one third of patients diagnosed with medulloblastoma succumb to their disease within 5 years 6 and surviving patients often have significant long-term adverse effects from current therapies. Identifying the underlying genetic events responsible for medulloblastomas can help guide the development of more effective therapies and refine the selection of currently available chemotherapy and radiotherapy. Recent efforts profiling transcriptional and DNA copy number changes in medulloblastoma have provided insights into the biological processes involved in these tumours and have underscored the molecular heterogeneity of this disease [2] [3] [4] . Based on these data, four broad subgroups have been established, known according to a consensus nomenclature as SHH, WNT, Group 3 and Group 4 (ref. 5).
The first genome-scale sequencing of protein coding regions in medulloblastoma was reported recently 7 . Altered genes encoding for histone modification proteins were identified in 20% of cases, most notably MLL2 and MLL3 (ref. 7) . This initial survey was limited by a small discovery sample size (22 patients), lack of subtype-specific analysis, and use of Sanger sequencing technology insensitive to variants present at low allelic fraction. Here we survey coding somatic mutations at deeper coverage in a larger cohort of 92 medulloblastoma/ normal pairs and assess these mutations in the context of specific molecular subtypes ( Supplementary Table 1 ).
In total, 1,908 mutations were detected within 1,671 out of 18,863 genes sequenced to a median of 1063 coverage (Supplementary Table 2 ). Confirmation of 20 candidate mutations in selected genes (CTNNB1, DDX3X, SMARCA4, TP53 and CTDNEP1) was performed by amplification of 48 exons using a microfluidic PCR device (Fluidigm) followed by single-molecule real-time sequencing (SMRT, Pacific Biosciences) (Supplementary Information). Sequence data was unavailable for one DDX3X mutation because of poor PCR amplification from the sample. All remaining 19 mutations were confirmed by this orthogonal method (median 73 redundant sub-reads, range 3-287, Supplementary Fig. 1 ).
A median of 16 somatic mutations (12 non-silent, 4 silent) per tumour was identified, corresponding to a mutation rate of 0.35 nonsilent mutations per megabase of callable sequence, less than most adult solid tumours and consistent with results from ref. 7 . Six of the twelve most frequently mutated tumours were from the oldest patients (16-31 years at diagnosis), consistent with increased mutation frequency in adult versus childhood medulloblastomas (P 5 7.7 3 10 25 , Wilcoxon rank-sum test, Supplementary Fig. 2 ).
To identify genes mutated at statistically significant frequencies across our cohort, we used the MutSig algorithm 8 which takes into account gene size, sample-specific mutation rate, non-silent to silent mutation ratios, clustering within genes, and base conservation across species. In our cohort of 92 samples, we identified 12 significantly mutated genes (q , 0.1, Table 1 and Supplementary Table 3 ). Strikingly, these genes were not mutated in c5 (Group 3) and c4 (Group 4) tumours with extensive somatic copy number alteration ( Fig. 1 ), indicating that these subtypes are driven primarily by structural variation, rather than base mutation. Not unexpectedly, CTNNB1 (b-catenin) and PTCH1 were the two most significantly mutated genes (see Table 1 and Fig. 1 ). Point mutations of CTNNB1 in combination with loss of chromosome 6 were found in all WNT subgroup tumours and were concurrent with several other recurrently mutated genes, namely CSNK2B, DDX3X, TP53 and SMARCA4. Mutations involving PTCH1 occurred exclusively in SHH subgroup tumours and mutations of genes associated with the hedgehog pathway were also restricted to this subgroup (P , 0.0001, Fisher's exact test). All but one of the tumours with PTCH1 mutations had somatic loss of 9q, resulting in hemizygosity for the mutant allele. The remaining tumour had apparent copy neutral loss-of-heterozygosity of 9q22. Other somatic mutations of hedgehog pathway members include a splice site mutation in SUFU, an in-frame deletion in WNT6, and missense mutations in GLI2, SMO, PRKACA, WNT2 and WNT2B.
Two patients with SHH subgroup tumours had germline variants in PTCH1, one with somatic loss of 9q resulting in hemizygosity for a lossof-function germline allele (MD-085, c.3030delC, p.Asn1011Thrfs*38), and the other with a substitution previously reported in patients with holoprosencephaly (MD-286, p.T1052M, ref. 9). Two additional cases (MD-097 and MD-335) had loss-of-function variants in SUFU (1 frameshift deletion and 1 nonsense) that began as heterozygotes in the germline and became hemizygous in the tumour, due to somatic loss of chromosome 10 in one case and copy neutral loss-of-heterozygosity in the other.
MLL2 was also subject to recurrent inactivating mutations, consistent with findings from ref. 7 and providing further evidence for dysregulated histone modification in medulloblastoma. Indeed, six G protein pathway suppressor 2  3  3  3  0  1  2  0  1 . 2 3 10 24  TP53  Tumour protein p53  3  3  3  0  3  0  0  0 . 0 3 9  KDM6A UTX, lysine (K)-specific demethylase 6A 3
Null, nonsense, frameshift or splice-site mutations; double null, null mutations co-occurring in a single tumour; q, q-value, false discovery rate (Benjamini-Hochberg procedure). See Supplementary Table 3 for further statistics and subtype analysis. 
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of the twelve most significantly mutated genes are involved in histone modification and/or related chromatin remodelling complexes (MLL2, GPS2, KDM6A, BCOR, SMARCA4 and LDB1; see Table 1 ). As a gene set, histone methyltransferases (HMTs) were enriched for somatic mutation with 21 tumours having apparent, predominantly loss-of-function, HMT mutations (q 5 5.8 3 10 29 ; Fig. 2 and Supplementary Table 4 ).
Subtype-specific MutSig analysis identified additional significant mutations of histone-modifying genes, MLL3 and HDAC2, in Group 4 tumours along with KDM6A mutations (q 5 0.039 and 0.066, see Supplementary Table 3 ). Mutations in KDM6A, interestingly, occurred exclusively in tumours with an i17q as the sole autosomal alteration (P 5 0.0023, Fisher's exact test) with the one female case with KDM6A mutation also having loss of a chromosome X. Notably, the two 'i17q only' tumours without KDM6A mutations had other histone-modifying enzymes mutated, namely THUMPD3, ZMYM3 and MLL3, perhaps suggesting a distinct biology for tumours with this karyotype.
Mutations in several genes encoding components of the nuclear co-repressor (N-CoR) complex were observed at a statistically significant frequency: BCOR in 3 tumours, GPS2 in 3 tumours, and LDB1 in 2 tumours. BCOR mutations have recently been reported at high frequency in retinoblastoma 10 and in 'copy-neutral' acute myelogenous leukaemia 11 . BCOR is located on the X-chromosome and two hemizygous frameshift mutants were found in tumours from males (allele fractions 0.90 and 0.92). A third nonsense mutation was also found in a male but at low allelic fraction (0.12), indicating a subclonal event. Two out of three BCOR mutations occurred in SHH subgroup tumours. LDB1 missense and nonsense mutations were found in two additional SHH tumours, both appearing hemizygous due to loss of 10q and complete chromosome 10 loss, respectively (allele fractions 0.81 and 0.78). Both BCOR and LDB1 promote assembly of the repressive N-CoR complex 12 and harbour apparent loss of function mutations. GPS2, which encodes a critical subunit of the N-CoR complex, a repressor of JNK/MAPK signalling through partnership with histone deacetylases 12 , was mutated in two Group 3 tumours. The GPS2 mutations cluster within amino acids 53-90, the domain critical for heterodimerization with NCOR2 (also known as SMRT) and interacting with a TBL1 amino-terminal domain tetramer to assemble the N-CoR repression complex 12 . Finally, an additional nonsense mutation in NCOR2 was identified in a single SHH subgroup tumour, underscoring the central role of N-CoR dysregulation in medulloblastoma development and particularly within the SHH subgroup.
Several genes encoding subunits of the SWI/SNF-like chromatinremodelling complex were also mutated in our cohort, including significant recurrent mutations of SMARCA4(Brg/BAF190), which encodes a DNA helicase with ATPase activity 13 and has been reported to be mutated in lung, ovarian, and pancreatic cancers 14 as well as medulloblastoma 15 . In our cohort, SMARCA4(Brg/BAF190) mutations clustered in helicase domains and occurred in three Group 3 tumours (significant within the c1 subtype, q 5 0.019), and one WNT tumour. In addition, mutations were found in the alternative ATPase subunit SMARCD2(Brm) (missense at a highly conserved residue) and two other members of the SWI/SNF complex, ARID1B(BAF250b) (2 base pairs (bp) frameshift deletion) and SMARCC2(BAF170) (splice site). These were all apparent loss-of-function mutations and occurred in SHH tumours. Thus, it seems that disruption of this complex is frequent across medulloblastomas.
New and hemizygous mutations were found in CTDNEP1 (previously known as DULLARD), a phosphatase with roles in Xenopus neural development through regulation of BMP receptors 16 , and as a direct regulator of LIPIN, an integral component of the mTOR complex 17 . CTDNEP1 mutations were found in two Group 3 tumours (significant within the subtype, q 5 0.0087), a 2-bp frameshift deletion and a substitution disruptive of a splice site. Both tumours have i17q chromosomes, resulting in loss of the wild-type allele at 17p13.
Mutations in DDX3X, an ATP-dependent RNA helicase with functions in transcription, splicing, RNA transport and translation 18 , were found in seven tumours, including half of the WNT pathway tumours (P 5 0.005, Fisher's exact test) and several SHH subgroup tumours. 12 ; yellow, other interaction domains as labelled (SANT domains binds DNA, CoRNR domains binds nuclear receptors, ANK repeats mediate a diversity of protein-protein interactions, and LIM-binding domains bind a common protein structural motif). c, RNA helicase domains: cyan, helicase and helicaseassociated (InterPro); red, RNA-binding and RNA polymerase sigma factor (InterPro); blue, ATP binding site; green, DEAD or DExH box motif. See Supplementary Table 1 for UniProt protein model identifiers.
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DDX3X mutations have recently been reported at low frequency in five other tumour types (Catalogue of Somatic Mutations in Cancer, COSMIC 15 ) but the significance of these mutations for DDX3X function remains unclear. To understand the consequence of observed point mutations on the physical structure of DDX3X, we mapped the mutations onto the previously reported crystal structure of DDX3X 19 and its orthologue DDX4 (also known as VASA, ref. 20) ( Fig. 3a; Supplementary Fig. 3 and Supplementary Table 5 ). The mutations seem to cluster in two structural domains, a helicase ATP-binding domain (residues 211-403) and a helicase carboxyterminal domain (residues 414-575). The location of these mutations indicates that they may alter DDX3X-RNA interaction ( Fig. 3a and Supplementary Table 5 ).
As half of the b-catenin mutated tumours contained concurrent DDX3X mutations, we investigated whether DDX3X could enhance the of ability b-catenin to transactivate a TCF4-luciferase reporter (TOPflash) and if DDX3X/b-catenin co-expression had a measureable effect on cell viability/proliferation. In combination with wild-type b-catenin, neither wild-type nor mutant DDX3X alone significantly transactivated the TOPflash reporter. However, in combination with mutant b-catenin (S33Y substitution), the majority of DDX3X point mutants in our cohort potentiated reporter activity (P , 0.05, Fig. 3b ). This potentiation was also apparent in cell viability assays in both HeLa (data not shown) and D425 medulloblastoma cell lines (P , 0.05, Fig. 3c ).
Given the apparent importance of DDX3X mutations in medulloblastoma, we searched the genes listed in the RNA Helicase Database (http://www.rnahelicase.org/) for low frequency mutations in medulloblastoma. We found five tumours with mutations within RNA helicase or RNA binding domains of DHX9, DHX32, DHX57, FANCM and SKIV2L ( Fig. 2 and Supplementary Table 6 ). The missense mutations were at conserved residues and predicted to be deleterious by the software packages SIFT, AlignGVGD and PolyPhen2. In addition, a frameshift insertion in SETX occurs upstream of, and probably disrupts, its RNA helicase domain. Overall, 15% of medulloblastomas seem to have some disruption of RNA helicase activity.
In summary, we report a next-generation sequencing analysis of medulloblastoma, the most common malignant brain tumour in children. Our results reveal mutations in several known pathways such as histone methylation (MLL2 and others), sonic hedgehog (PTCH1, SUFU and others) and Wnt (CTNNB1 and others), and also previously unrecorded mutations in genes including DDX3X, BCOR, LDB1 and GPS2. Our preliminary functional studies implicate DDX3X as a candidate component of pathogenic WNT/b-catenin signalling. In a broader sense, DDX3X mutations have recently been reported in chronic lymphocytic leukaemia 21 and head and neck cancers 22 , both of which have subsets of tumours with dysregulated WNT signalling. Studies investigating whether mutant DDX3X functions together with b-catenin in these contexts should provide additional insights into this multifaceted molecule and open potential avenues for novel therapies. Finally, the delineation of nuclear receptor co-repressor complex molecules as altered in medulloblastoma provides new insight into the pathogenesis of this deadly childhood disease.
METHODS SUMMARY
Informed consent was provided by families of medulloblastoma patients treated at Children's Hospital Boston, The Hospital for Sick Children, Toronto, Canada, and institutions contributing to the Children's Oncology Group/Cooperative Human Tissue Network, under approval and oversight by their respective Internal Review Boards. All tumours were obtained at the initial surgical resection and recurrent tumours were excluded from our analysis. Haematoxylin-and eosin-stained slides of tumour samples were reviewed by a pathologist to confirm the diagnosis of medulloblastoma, determine histological subtype when possible, and assess tumour purity. DNA was isolated from tumour specimens and matched peripheral blood as previously described 2 . Exome sequencing of DNA from 92 tumour/normal pairs was performed using in-solution hybrid-capture of 193,094 exons from 18,863 micro RNA (miRNA)-and protein-coding genes, followed by sequencing of 76 bp paired-end reads using Illumina sequencing-by-synthesis technology 23 . Reads were aligned to human genome build GRCh37 24 using a Burrows-Wheeler aligner (BWA) 25 . The ,33-megabase target region was sequenced to 1063 mean coverage in each sample (range 73-234). Gene expression data and copy number profiles (derived from SNP microarrays or sequence data) were used to assign each tumour to a subgroup using published criteria 2 . Our cohort consisted of 6 WNT (c6), 23 SHH (c3), 33 Group 3 (12 c1, 21 c5), and 30 Group 4 (12 c2, 18 c4) tumours (see Supplementary Table 1 for case annotations). Mutations were detected using muTect, annotated using Oncotator 26 , and manually reviewed using the Integrated Genomics Viewer (IGV) 27 . For validation, PCR on Access Array microfluidic chips (Fluidigm) was followed by single-molecule real-time sequencing (Pacific Biosciences) as per manufacturer's instructions. Sub-reads were extracted and assigned to samples using manufacturer's and custom software, and aligned to the hg19 (GRCh37) build of the human reference genome sequence using BWA-SW 25 . Candidate mutations were confirmed by manual review using IGV 27 (Supplementary Fig. 1 ). See Supplementary Information and http://www.broadinstitute.org/cancer/cga/ for complete descriptions of materials and methods. Displayed are the residues mutated in the amino-terminal recA-like domain (R276K, D354H, R376C) and C-terminal recA-like domain (D506Y, R528H, R534H, P568L). Colouring: light blue, DDX3X residues 166-405; dark blue, DDX3X residues 406-582; cyan, single-stranded RNA; magenta and green, Mg-ATP analogue. Molecular graphics images were produced using the University of San Francisco Chimera package 29 (http://www.cgl.ucsf.edu/chimera). b, Mutant DDX3X potentiates mutant b-catenin transactivation of TOPflash promoter. Represented is relative luciferase activity in 293T cells co-transfected with TOPflash reporter, FOPflash control, and either wild-type or mutant DDX3X in combination with wild-type or mutant b-catenin. One-dimensional model of DDX3X displayed above bar graphs to illustrates the position of the mutations. WT, wild type. c, Cell viability assays of medulloblastoma D425 cells stably transduced with either wild-type or mutant DDX3X lentivirus in combination with either wild-type or mutant b-catenin lentivirus. For b and c, error bars depict the standard deviation of the mean from five replicate experiments performed for each condition. Student's t-tests were performed to evaluate significance of differences in TOPflash intensity or cell proliferation value distributions as follows: increases with DDX3X alone versus empty vector, increases with wild-type b-catenin versus DDX3X alone, increases with mutant b-catenin versus DDX3X alone, and increases with mutant b-catenin versus wild-type b-catenin.
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